Endo Health to slash 15 percent jobs, looks to sell some assets
(Reuters) - Endo Health Solutions Inc said it plans to cut about 15 percent of its workforce and explore strategic alternatives for some assets as the company looks to cut...
Home > Reviews
All Stories
FDA allows generic forms of Endo Health’s Opana ER painkiller
(Reuters) - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise...
FDA allows generic forms of Endo Health’s Opana ER painkiller
(Reuters) - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise...
Vivus gets FDA nod to sell diet pill via retail pharmacies
(Reuters) - Vivus Inc President Peter Tam said U.S. health regulators' approval to sell its diet pill Qsymia through retail pharmacies removed "a major barrier" to the drug's adoption and...
Vivus gets FDA nod to sell diet pill via retail pharmacies
(Reuters) - Vivus Inc President Peter Tam said U.S. health regulators' approval to sell its diet pill Qsymia through retail pharmacies removed "a major barrier" to the drug's adoption and...
Affymax may file for bankruptcy; cuts 75 percent of workforce
(Reuters) - Drugmaker Affymax Inc said it was considering selling itself or filing for bankruptcy among a range of alternatives, as it struggles to stay afloat following the recent recall...
Dynavax may have to repitch hepatitis B vaccine for smaller market
(Reuters) - Dynavax Technologies Inc may need to repitch its hepatitis B vaccine for a smaller patient population, after U.S. health regulators declined to approve the vaccine for adults -...
Dynavax may have to repitch hepatitis B vaccine for smaller market
(Reuters) - Dynavax Technologies Inc may need to repitch its hepatitis B vaccine for a smaller patient population, after U.S. health regulators declined to approve the vaccine for adults -...
Vivus diet pill sales disappoint, shares fall
(Reuters) - Sales of Vivus Inc's diet pill Qsymia failed to meet Wall Street expectations even as the company spent more to promote the drug, the first weight-loss pill to...
Slow and steady can win the diet drug race
(Reuters) - Vivus Inc, vying to create the world's first billion-dollar weight-loss pill, is taking a cautious approach to marketing in an attempt to overcome the skepticism, safety concerns and...